永安藥業(002365.SZ):永安康健目前產能充沛,易加能產品庫存充足
格隆匯5月30日丨永安藥業(002365.SZ)在投資者互動平臺表示,1、子公司永安康健易加能產品於2024年年底前正式上線運營,經過持續的營銷推廣,目前已有較好的市場反饋,但當前的市場表現是基於上市初期的短期數據,之後將持續監測市場動態,積極調整營銷策略,以期持續提升產品銷量。永安康健目前產能充沛,易加能產品庫存充足,能夠滿足市場需求,不存在供不應求的現象。2、子公司永安康健易加能自有品牌產品均符合國家食品安全標準,按照產品說明食用,不會對身體健康造成負面影響,請廣大消費者放心選購、安心食用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.